November 23, 2026

FDA panel revisits Avandia diabetes drug

Reuters

.

Reuters

Published : 05 Jun 2013, 04:11 PM

Updated : 09 Aug 2022, 10:45 AM

A US Food and Drug Administration panel of outside experts reopened one of the biggest drug controversies in recent years on Wednesday at a meeting where they will decide whether to recommend lifting marketing restrictions on GlaxoSmithKline Plc's Avandia diabetes drug.

The two-day FDA advisory committee meeting is not expected to bring about a major boost in sales for the onetime blockbuster product. But its findings may help revive the credibility of the British company's original research and shed light on today's US regulatory approach to the health risks posed by new drugs.

Avandia was once the world's best-selling treatment for type 2 diabetes, with annual sales of $3.2 billion. Its use was heavily restricted in 2010, though, because of the possibility of increased risks of heart attack and stroke. It was withdrawn from the market in Europe in 2010, and only 3,000 people in the United States take it today.

The advisory panel session on Wednesday opened with a critical assessment of a Duke University "readjudication" of Glaxo's Record safety study that is the basis for the expert panel's deliberations over the next two days. FDA staff said in briefing documents earlier this week that the Duke analysis backed Glaxo's safety findings for Avandia but also found that scores of smaller trials raised questions over whether the pill increases heart risks.

Dr. Thomas Marciniak, medical team leader of FDA's Division of Cardiovascular and Renal Products, warned panelists that the readjudication by the Duke Clinical Research Institute cannot be considered independent. The effort was financed by and conducted in collaboration with the drugmaker, which has also paid thousands of dollars in consulting fees to Duke's lead investigator, he said.

"They got it right for what they were allowed to say," said Marciniak. Some Record documents were redacted, he said, and original records of potential adverse events were deleted.

"The readjudication was limited because it relies largely on the original database and source documents in collaboration with GSK," he added.

Marciniak said it would have been better for FDA to handle all the data on Avandia with company authorization. He offered to treat Glaxo Chief Executive Officer Andrew Witty and five of the CEO's colleagues to dinner at an expensive London restaurant if his views prove wrong.

NO AVANDIA PROMOTION

Glaxo has said it has no plans to promote Avandia again, even if the FDA panel recommends lifting restrictions on sales of the drug, whose generic name is rosiglitazone maleate.

"The FDA is putting significant resources behind this meeting, but even if they allow Avandia to return to full marketing strength, I don't think that would do much for Glaxo from a business standpoint," said Morningstar analyst Damien Conover.

Conover said there was only a slight chance that the meeting will prompt the FDA to ease sales restrictions significantly.

"But if they do, that could signal that the FDA is a little more willing to accept more side effects than it has in the past," Conover said.

Glaxo has settled lawsuits filed by tens of thousands of US patients who had taken Avandia and claimed the company failed to inform them about risks. Several thousand other cases remain pending.

European regulators required the Record safety trial because of concerns that drugs in Avandia's class - called thiazolidinediones - may increase the risk of heart failure.

The trial met its primary objective by showing that Avandia, when combined with either metformin or a member of an older class of diabetes pills called sulfonylureas, was at least as safe as the combination of metformin and a sulfonylurea.

But the FDA clamped down on Avandia's use in September 2010 after most members of an FDA advisory panel voted that the Record data raised significant concerns that the drug might indeed pose a greater risk of heart attack and stroke than standard treatments, including fellow thiazolidinedione Actos (pioglitazone) from Takeda Pharmaceutical Co's.

Although the FDA allowed Avandia to remain on the US market, the agency commissioned the Duke Clinical Research Institute to analyze results of the Record trial to better assess the drug's safety and to examine criticisms that the trial was poorly designed and its data was mishandled.

But in a briefing document on Monday ahead of the two-day meeting this week, the FDA said the study's methods and analyses passed muster with the Duke group. Moreover, it said the group, part of Duke University's Medical School, appeared to agree that Avandia was not associated in the Record trial with increased risk of heart attacks and stroke.

Avandia had been on a downhill slide since 2007, when Dr. Steven Nissen, head of cardiology at the Cleveland Clinic, said an analysis of 42 studies showed Avandia increased the risk of a heart attack by a 43 percent.

The FDA now requires heart-safety data for new diabetes drugs because of the Avandia experience. Sales of the drug, which was approved in 1999 and makes patients more sensitive to their own insulin, plunged after the negative publicity.

Glaxo last July agreed to pay $3 billion to settle what US officials called the largest case of healthcare fraud in the nation's history. The agreement resolved allegations that the company failed through 2007 to provide the FDA with safety data on Avandia and marketed other drugs improperly.

Related Stories